HOME > BUSINESS
BUSINESS
- Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
- Combination Drug Containing JR-051 to Be Developed: JCR
July 23, 2012
- Azilva Ranked No. 1 in Both HP, GP Markets for 2 Straight Months: Rep Track Survey
July 23, 2012
- Patent Cliff for Kipres Looms; Will Kyorin Continue to Stand Alone in Respiratory Disease Field?
July 23, 2012
- HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
- Aricept Successor BACE Inhibitor Reduced Aβ in PI Studies: Eisai
July 20, 2012
- Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
- Sandoz Initiates Voluntary Recall of Carboplatin, Shipment Suspended
July 20, 2012
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
- Alfresa HD to Make Tokiwa Yakuhin Wholly-Owned Subsidiary
July 19, 2012
- OTC Market Decreases 0.4% to 611.5 Billion Yen in 2011: Fuji-Keizai
July 19, 2012
- Eisai Ties Up with Verastem for Generation of Novel Wnt Signal Inhibitors
July 19, 2012
- Chugai, Taisho File NDA for Novel Osteoporosis Treatment
July 19, 2012
- Chugai Opens Singapore Research Subsidiary, Aims to Produce Over 5 Antibody Candidates per Year
July 18, 2012
- Nippon Kayaku Initiates PIII Study of NK105 for Breast Cancer
July 18, 2012
- Chairman Humer of Roche Criticizes Drug Pricing Policy in Japan as“Extremely Negative”
July 18, 2012
- Nippon Kayaku Launches New Specification of Generic Kytril
July 18, 2012
- China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
- MSD to Launch Oral Rotavirus Vaccine RotaTeq on July 20
July 18, 2012
- Janssen Applies for HIV Drug Prezista Naive Tablet 800 mg
July 17, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…